Table 3.
Model-based tobacco outcome measures and adjusted rate ratios separated by low and moderate/high baseline nicotine dependence levels for each treatment group (NAC and PBO) and the entire cigarette smoking sub-sample (n=117).
| Outcome | Cohort | Mean (SEM) | Rate Ratio (95% CI) ǂ | |
|---|---|---|---|---|
| NAC | PBO | (PBO vs. NAC) | ||
| Weekly Outcomes Measured During Treatment | ||||
| Overall | 5.4 (0.2) | 5.8 (0.2) | 1.13 (0.92–1.38) | |
| Cigarette Smoking Days | Low FTND | 4.5 (0.4) | 5.6 (0.4) | 1.40 (1.02–1.92) |
| High FTND | 6.3 (0.3) | 6.1 (0.3) | 0.90 (0.70–1.17) | |
| Overall | 6.5 (0.9) | 7.4 (0.9) | 1.21 (0.86–1.70) | |
| Cigarettes Per Day | Low FTND | 3.0 (1.3) | 4.5 (1.4) | 1.54 (0.92–2.57) |
| High FTND | 10.0 (1.1) | 10.4 (1.2) | 0.96 (0.62–1.47) | |
| Outcomes Measured During Follow-up | ||||
| Overall | 5.5 (0.4) | 5.3 (0.5) | 1.08 (0.97–1.22) | |
| Cigarette Smoking Days | Low FTND | 4.3 (0.6) | 5.7 (0.7) | 1.39 (1.16–1.66) |
| High FTND | 6.6 (0.5) | 4.9 (0.6) | 0.85 (0.75–0.97) | |
| Overall | 6.5 (0.9) | 5.7 (1.0) | 0.94 (0.74–1.20) | |
| Cigarettes Per Day | Low FTND | 2.8 (1.4) | 5.7 (1.6) | 1.41 (0.94–2.10) |
| High FTND | 10.2 (1.1) | 5.8 (1.4) | 0.63 (0.49–0.82) | |
The rate ratio (RR) represents the increased risk of smoking outcome rates per week in the Placebo (PBO) group as compared to NAC and is derived from the Poisson regression model. RR results are shown adjusted for study treatment, visit number, baseline smoking dependence level, race, and concurrent cannabis use. In the final cigarette smoking days models, site and site x treatment covariate effects were insignificant, thus site was included in the model as a random effect. In the final CPD models, site was a significant predictor of CPD and was retained in the model as a covariate.
p<0.05